Rezafungin (Rezzayo®). HTA ID: 24007

Assessment Status Rapid Review Complete
HTA ID 24007
Drug Rezafungin
Brand Rezzayo®
Indication Rezafungin (Rezzayo®) is indicated for the treatment of invasive candidiasis in adults.
Assessment Process
Rapid review commissioned 22/03/2024
Rapid review completed 26/03/2024
Rapid review outcome A full HTA is not recommended. The NCPE recommends that rezafungin not be considered for reimbursement at the submitted price*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.